BridgeMD
Compares treatment options for Embryo Transfer
Official title Letrozole-stimulated Cycle Strategy Versus Artificial Cycle Strategy (LETSACT)
ClinicalTrials.gov ID: NCT06372119
What this study is testing
- What it's testing
- The goal of this randomized clinical trial is to evaluate the effectiveness of the letrozole-stimulated cycle strategy versus the artificial cycle strategy for endometrial preparation in women with irregular menstrual cycles after one cycle of endometrial preparation. The primary question it aims to answer is: Does the letrozole-stimulated cycle strategy for endometrial preparation result in a higher live birth rate compared to the artificial cycle strategy in women with irregular menstrual cycles after one cycle of endometrial preparation?
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 42, women only. Healthy volunteers may be eligible.
You may be able to join if
- Aged between 18 - 42.
- Irregular menstrual cycle (\ 35 days or \< 8 cycles/years).
- Indicated for endometrial preparation.
- Transfer of only one blastocyst.
- Not participating in any other trials.
You likely can't join if
- Allergy to letrozole or Ovitrelle or oral estradiol valerate or micronized progesterone
- Having embryos from either oocyte donation or PGT (pre-implantation genetics testings) cycles.
- Ovarian cysts that are unrelated to the oocyte pick-up.
- Confirmed diagnosis with recurrent pregnancy loss (RPL) according to ESHRE guideline 2023, recurrent implantation failure (RIF) according to ESHRE...
- Endometrial abnormalities include endometrial hyperplasia, intrauterine adhesions, endometrial polyp, and chronic endometritis.
- Uterine abnormalities include leiomyomas L0, L1, or L2 (according to FIGO 2011); adenomyosis (according to MUSA 2022); congenital uterine...
See the full eligibility criteria
- Aged between 18 - 42.
- Irregular menstrual cycle (\ 35 days or \< 8 cycles/years).
- Indicated for endometrial preparation.
- Transfer of only one blastocyst.
- Not participating in any other trials.
- Allergy to letrozole or Ovitrelle or oral estradiol valerate or micronized progesterone
- Having embryos from either oocyte donation or PGT (pre-implantation genetics testings) cycles.
- Ovarian cysts that are unrelated to the oocyte pick-up.
- Confirmed diagnosis with recurrent pregnancy loss (RPL) according to ESHRE guideline 2023, recurrent implantation failure (RIF) according to ESHRE 2023 good practice recommendations.
- Endometrial abnormalities include endometrial hyperplasia, intrauterine adhesions, endometrial polyp, and chronic endometritis.
- Uterine abnormalities include leiomyomas L0, L1, or L2 (according to FIGO 2011); adenomyosis (according to MUSA 2022); congenital uterine abnormalities, include didelphus, arcuate, unicornuate, bicornuate, septate...
- Untreated hydrosalpinx.
The study team makes the final eligibility decision.
Where it's taking place
- Ho Chi Minh City, Ho Chi Minh City, Vietnam
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 42 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Ho Chi Minh City, Ho Chi Minh City, Vietnam. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.